Literature DB >> 28880010

Chronic pancreatitis.

Jorg Kleeff1,2, David C Whitcomb3, Tooru Shimosegawa4, Irene Esposito5, Markus M Lerch6, Thomas Gress7, Julia Mayerle8, Asbjørn Mohr Drewes9, Vinciane Rebours10, Fatih Akisik11, J Enrique Domínguez Muñoz12, John P Neoptolemos13.   

Abstract

Chronic pancreatitis is defined as a pathological fibro-inflammatory syndrome of the pancreas in individuals with genetic, environmental and/or other risk factors who develop persistent pathological responses to parenchymal injury or stress. Potential causes can include toxic factors (such as alcohol or smoking), metabolic abnormalities, idiopathic mechanisms, genetics, autoimmune responses and obstructive mechanisms. The pathophysiology of chronic pancreatitis is fairly complex and includes acinar cell injury, acinar stress responses, duct dysfunction, persistent or altered inflammation, and/or neuro-immune crosstalk, but these mechanisms are not completely understood. Chronic pancreatitis is characterized by ongoing inflammation of the pancreas that results in progressive loss of the endocrine and exocrine compartment owing to atrophy and/or replacement with fibrotic tissue. Functional consequences include recurrent or constant abdominal pain, diabetes mellitus (endocrine insufficiency) and maldigestion (exocrine insufficiency). Diagnosing early-stage chronic pancreatitis is challenging as changes are subtle, ill-defined and overlap those of other disorders. Later stages are characterized by variable fibrosis and calcification of the pancreatic parenchyma; dilatation, distortion and stricturing of the pancreatic ducts; pseudocysts; intrapancreatic bile duct stricturing; narrowing of the duodenum; and superior mesenteric, portal and/or splenic vein thrombosis. Treatment options comprise medical, radiological, endoscopic and surgical interventions, but evidence-based approaches are limited. This Primer highlights the major progress that has been made in understanding the pathophysiology, presentation, prevalence and management of chronic pancreatitis and its complications.

Entities:  

Mesh:

Year:  2017        PMID: 28880010     DOI: 10.1038/nrdp.2017.60

Source DB:  PubMed          Journal:  Nat Rev Dis Primers        ISSN: 2056-676X            Impact factor:   52.329


  95 in total

Review 1.  Chronic Pancreatitis and the Development of Pancreatic Cancer.

Authors:  Hemanth K Kandikattu; Sathisha U Venkateshaiah; Anil Mishra
Journal:  Endocr Metab Immune Disord Drug Targets       Date:  2020       Impact factor: 2.895

Review 2.  The pancreatic cancer genome revisited.

Authors:  Akimasa Hayashi; Jungeui Hong; Christine A Iacobuzio-Donahue
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2021-06-04       Impact factor: 46.802

3.  Elastase 3B mutation links to familial pancreatitis with diabetes and pancreatic adenocarcinoma.

Authors:  Paul C Moore; Jessica T Cortez; Chester E Chamberlain; Diana Alba; Amy C Berger; Zoe Quandt; Alice Chan; Mickie H Cheng; Jhoanne L Bautista; Justin Peng; Michael S German; Mark S Anderson; Scott A Oakes
Journal:  J Clin Invest       Date:  2019-08-01       Impact factor: 14.808

Review 4.  Practical guide to the management of chronic pancreatitis.

Authors:  Mustafa Jalal; Jennifer A Campbell; Andrew D Hopper
Journal:  Frontline Gastroenterol       Date:  2018-09-07

5.  Factors Associated With Frequent Opioid Use in Children With Acute Recurrent and Chronic Pancreatitis.

Authors:  Emily R Perito; Tonya M Palermo; John F Pohl; Maria Mascarenhas; Maisam Abu-El-Haija; Bradley Barth; Melena D Bellin; Douglas S Fishman; Steven Freedman; Cheryl Gariepy; Matthew Giefer; Tanja Gonska; Melvin B Heyman; Ryan W Himes; Sohail Z Husain; Tom Lin; Quin Liu; Asim Maqbool; Brian McFerron; Veronique D Morinville; Jaime D Nathan; Chee Y Ooi; Sue Rhee; Sarah Jane Schwarzenberg; Uzma Shah; David M Troendle; Steven Werlin; Michael Wilschanski; Yuhua Zheng; Miriam Bridget Zimmerman; Mark Lowe; Aliye Uc
Journal:  J Pediatr Gastroenterol Nutr       Date:  2020-01       Impact factor: 2.839

6.  Single nucleotide polymorphisms in CEL-HYB1 increase risk for chronic pancreatitis through proteotoxic misfolding.

Authors:  Brett M Cassidy; Sammy Zino; Karianne Fjeld; Anders Molven; Mark E Lowe; Xunjun Xiao
Journal:  Hum Mutat       Date:  2020-09-09       Impact factor: 4.878

7.  Adipose Stem Cell Therapy for Chronic Pancreatitis.

Authors:  Moufida Ben Nasr; Davide Frumento; Paolo Fiorina
Journal:  Mol Ther       Date:  2017-10-19       Impact factor: 11.454

8.  The Liverpool duodenum-and spleen-preserving near-total pancreatectomy can provide long-term pain relief in patients with end-stage chronic pancreatitis.

Authors:  A R G Sheel; R D Baron; L D Dickerson; P Ghaneh; F Campbell; M G T Raraty; V Yip; C M Halloran; J P Neoptolemos
Journal:  Langenbecks Arch Surg       Date:  2019-11-20       Impact factor: 3.445

9.  The histopathology of SPINK1-associated chronic pancreatitis.

Authors:  Terrell E Jones; Melena D Bellin; Dhiraj Yadav; Martin L Freeman; Sarah J Schwarzenberg; Adam Slivka; Jennifer S Chennat; Gregory J Beilman; Srinath Chinnakotla; Timothy L Pruett; Varvara Kirchner; Abhinav Humar; Martin Wijkstrom; Amer H Zureikat; Marina N Nikiforova; Abigail I Wald; David C Whitcomb; Aatur D Singhi
Journal:  Pancreatology       Date:  2020-10-16       Impact factor: 3.996

10.  Men1 maintains exocrine pancreas homeostasis in response to inflammation and oncogenic stress.

Authors:  Amanda R Wasylishen; Chang Sun; Gilda P Chau; Yuan Qi; Xiaoping Su; Michael P Kim; Jeannelyn S Estrella; Guillermina Lozano
Journal:  Proc Natl Acad Sci U S A       Date:  2020-03-10       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.